UBS AM
INSY

UBS AM’s Insys Therapeutics, Inc. INSY Stock Holding History

UBS AM’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,800
Closed -$126K – 2822
2018
Q1 		$126K Buy
20,800
+4,400
+27% +$36.3K ﹤0.01% 2444
2017
Q4 		$158K Hold
16,400
– – ﹤0.01% 2357
2017
Q3 		$146K Hold
16,400
– – ﹤0.01% 2322
2017
Q2 		$207K Hold
16,400
– – ﹤0.01% 2205
2017
Q1 		$172K Buy
+16,400
New +$175K ﹤0.01% 2228
2016
Q4 		– Sell
-17,800
Closed -$210K – 2769
2016
Q3 		$210K Hold
17,800
– – ﹤0.01% 2442
2016
Q2 		$230K Hold
17,800
– – ﹤0.01% 2365
2016
Q1 		$285K Sell
17,800
-1,500
-8% -$28.5K ﹤0.01% 2242
2015
Q4 		$553K Buy
19,300
+1,800
+10% +$49.9K ﹤0.01% 2000
2015
Q3 		$498K Sell
17,500
-3,700
-17% -$136K ﹤0.01% 2020
2015
Q2 		$762K Buy
21,200
+1,100
+5% +$34.3K ﹤0.01% 1817
2015
Q1 		$584K Buy
20,100
+400
+2% +$10.6K ﹤0.01% 1901
2014
Q4 		$415K Buy
19,700
+1,800
+10% +$35.6K ﹤0.01% 2044
2014
Q3 		$347K Hold
17,900
– – ﹤0.01% 2060
2014
Q2 		$280K Buy
+17,900
New +$289K ﹤0.01% 2225

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

UBS AM's INSY Position: Q2 2018 in Review

UBS AM sold out of Insys Therapeutics, Inc. (INSY) in Q2 2018, closing a stake of 20,800 shares — an estimated $126K sold.

UBS AM first reported a position in INSY in Q2 2014 and held it in 15 quarters. The position peaked at $762K in Q2 2015. 103 funds tracked by Wall St. Rank hold INSY as of Q2 2018.

  • UBS AM reported no remaining Insys Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • UBS AM sold 20,800 Insys Therapeutics, Inc. shares in Q2 2018, an estimated $126K.
  • UBS AM first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 15 quarters.
  • UBS AM's Insys Therapeutics, Inc. position peaked at $762K in Q2 2015.
  • 103 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2018.

Based on UBS AM's 13F filing for Q2 2018, filed 14 Aug 2018.